"www.healthbusiness.nl"

FRIDAY, Jan. 27 — Inlyta (axitinib) has been approved by the U.S. Food and Drug Administration to treat advanced renal cell carcinoma in people who haven’t responded to another drug.
Renal cell carcinoma is a form of kidney cancer that begins in…

Lees meer..

This entry was posted on Saturday, January 28th, 2012 at 6:00 am and is filed under Medicijnen. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.